Mankind Pharma receives 'Leader' category ESG rating from Niche99
Mankind Pharma Limited received a 'Leader' category ESG rating of 68.21 from Niche99 ESG Ratings for FY 2025-26. The rating was assigned independently by Niche99 based on public disclosures.
While a positive ESG rating is good, this announcement is an update based on publicly available data and does not involve any new strategic initiatives, financial performance changes, or direct business impact.
The company received a 'Leader' category ESG rating, which is generally viewed positively by investors and stakeholders.
Mankind Pharma Limited has been assigned an ESG rating of 68.21 under the 'Leader' category by Niche99 ESG Ratings. This rating is based on publicly available disclosures for the fiscal year 2025-26.
It is important to note that Mankind Pharma did not engage Niche99 for this rating; the report was prepared independently by Niche99 based on information in the public domain.
The company has made this disclosure available on its website, www.mankindpharma.com, in accordance with Regulation 30 and 51 of the SEBI Listing Regulations.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under esg reports. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.